Sangivamycine

Sangivamycin (NSC 65346), a nucleoside analog, is a potent inhibitor of protein kinase C (PKC) with an Ki of 10 μM. Sangivamycin has potent antiproliferative activity against a variety of human cancers[1][2].

18417-89-5

NSC 65346; BA-90912

12352005

H300

Nucleoside Antimetabolite/Analog; PKC

Natural Products

Cell Cycle/DNA Damage; Epigenetics; TGF-beta/Smad

Cancer-Kinase/protease

Cancer

https://www.medchemexpress.com/sangivamycin.html

10mM

97.68

DMSO : 100 mg/mL (ultrasonic)

OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=NC=NC(N)=C3C(C(N)=O)=C2)O1

C12H15N5O5

309.28

H300

[1]Loomis CR, Bell RM. Sangivamycin, a nucleoside analogue, is a potent inhibitor of protein kinase C. J Biol Chem. 1988;263 (4) :1682-1692.|[2]Lee SA, et al. The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation. J Biol Chem. 2007;282 (20) :15271-15283.

Room Temperature

-20°C, 3 years; 4°C, 2 years (Powder)

http://file.medchemexpress.com/batch_PDF/HY-118384/Sangivamycin-SDS-MedChemExpress.pdf

Natural Products

No Development Reported